Generation Bio Co. GBIO
Institutional shares held
41.5 Million
116K
calls
0
puts
Total value of holdings
$168M
$468K
calls
$0
puts
Market Cap
$239M
59,011,200
Shares Out.
Institutional ownership
70.3%
# of Institutions
60
We take great care to ensure that the data presented and summarized in this overview for Generation Bio Co. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GBIO
View all-
Price T Rowe Associates Inc Baltimore, MD8.46MShares$34.3 Million0.0% of portfolio
-
Atlas Venture Life Science Advisors, LLC8.28MShares$33.5 Million0.58% of portfolio
-
Black Rock Inc. New York, NY3.29MShares$13.3 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY2.97MShares$12 Million0.05% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.58MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.3MShares$9.31 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.94MShares$7.88 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$5 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY1.06MShares$4.31 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.06MShares$4.3 Million0.0% of portfolio
Latest Institutional Activity in GBIO
Top Purchases
Top Sells
About GBIO
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at GBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,548
-0.11%
|
$0
$0.43 P/Share
|
|
Jul 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,273
+0.38%
|
-
|
|
Jul 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.24%
|
$0
$0.43 P/Share
|
|
Jul 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,147
+0.81%
|
-
|
|
Jul 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-1.3%
|
$0
$0.43 P/Share
|
|
Jul 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,592
+4.24%
|
-
|
|
Jul 15
2025
|
Kevin John Conway Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
173
-0.94%
|
$0
$0.43 P/Share
|
|
Jul 15
2025
|
Kevin John Conway Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
587
+3.08%
|
-
|
|
Jul 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
983
-4.45%
|
$0
$0.43 P/Share
|
|
Jul 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,347
+13.16%
|
-
|
|
Apr 15
2025
|
Kevin John Conway Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
173
-0.96%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Kevin John Conway Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
587
+3.15%
|
-
|
|
Apr 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
983
-4.98%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Yalonda Howze CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,347
+14.51%
|
-
|
|
Apr 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-1.99%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Antoinette Paone CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,592
+6.33%
|
-
|
|
Apr 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,548
-0.11%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,274
+0.39%
|
-
|
|
Apr 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.26%
|
$0
$0.37 P/Share
|
|
Apr 15
2025
|
Phillip Samayoa CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,147
+0.88%
|
-
|
Last 12 Months Summary
Buy / Acquisition
263K
Shares
From
8
Insiders
| Exercise of conversion of derivative security | 52.2K shares |
|---|---|
| Open market or private purchase | 211K shares |
Sell / Disposition
16K
Shares
From
7
Insiders
| Payment of exercise price or tax liability | 16K shares |
|---|